ライフサイエンスコーパス: diagnostic use

1 eatment protocols towards true point-of-care diagnostic use.

2 aptation of new methods for routine clinical diagnostic use.

3 al human sweat for potential cystic fibrosis diagnostic use.

4 orter in the context of their therapeutic or diagnostic use.

5 ing this method into a clinically applicable diagnostic use.

6 gets available for potential therapeutic and diagnostic use.

7 of such reagents may have potential clinical diagnostic use.

8 their ambiguous physical origin limits their diagnostic use.

9 of the FilmArray respiratory panel (BioFire Diagnostics) using 129 respiratory specimens collected i

10 rating the feasibility of performing medical diagnostics using a logic gate design.

11 promising amyloid-beta radioligand both for diagnostic use and for evaluation of disease-modifying t

12 Specifically, we discuss the diagnostic use and potential of serologic tests based on

13 This makes routine diagnostic use and re-analysis of legacy data collection

14 These rapid tests are not recommended for diagnostic use, and further research is required to info

15 Many tests have both screening and diagnostic uses, and it is only the context in which the

16 Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specifici

17 Traditional technologies for molecular diagnostics using blood are limited to laboratory use be

18 rapid field deployment of nucleic acid-based diagnostics using consumer-class quadcopter drones.

19 ave been conventionally assessed in clinical diagnostics using cytogenetic or microarray testing.

20 T. gondii infection to optimize the PCR for diagnostic use, define its sensitivity, and characterize

21 Molecular structure-based diagnostics using genus- and species-specific PCR, RFLP

22 Improved diagnostics, using imaging, genetics, and biomarkers, ar

23 d develop them for research, therapeutic and diagnostic uses, improvements are needed in our ability

24 e number of new protein markers approved for diagnostic use in clinical laboratories.

25 S. Food and Drug Administration for in vitro diagnostic use in March 2007.

26 se staging in CHC continue to be refined for diagnostic use in other chronic liver disease such as NA

27 Molecular biomarkers are needed for diagnostic use in periodontal diseases.

28 ernative techniques could provide adjunctive diagnostic use in the context of difficult-to-diagnose T

29 sis techniques, we demonstrate that standard diagnostics used in the field are limited in their abili

30 e pathobiology of cancer and other diseases, diagnostics using in vivo liquid biopsy, and drug delive

31 he immunological mechanisms underlying their diagnostic use is still incomplete.

32 Although these have yet to be validated for diagnostic use, it is likely that testing for myositis-s

33 Once the (18)F tracers become available for diagnostic use, large-scale longitudinal studies will be

34 vaginalis PCR performed better than routine diagnostics using microscopy for women and culture for m

35 and overall mortality in patients with post-diagnostic use of cholera vaccine compared with matched

36 These data have important implications for diagnostic use of colon imaging tests.

37 Conclusions and Relevance: Diagnostic use of DSCMs shows promising correlation to f

38 bolic stress role in tumor survival, and the diagnostic use of imaging in prostate cancer were discus

39 ticle summarizes our current concepts on the diagnostic use of MIBG in children.

40 These results have implications for the diagnostic use of serum cystatin C as a marker of kidney

41 and "specificity" produces confusion in the diagnostic use of sophisticated laboratory test results.

42 There are limited data on the diagnostic use of the hepatic iron index in patients wit

43 atures in muscle, providing evidence for the diagnostic use of the technique, as well as insight into

44 Our main focus will be in describing the diagnostic uses of ultrasound to identify cardiac, pulmo

45 Finally, the broad range of diagnostic uses of US in these patients is presented, in

46 erence may provide Zher2 with advantages for diagnostic use or even for delivery of therapeutic agent

47 assay (Simplexa Flu A/B & RSV Direct; Focus Diagnostics) using respiratory swabs (n = 197).

48 Component-resolved diagnostics using specific IgE to 2 S albumins has shown

49 INTRODUCTION: Component-resolved diagnostics using specific IgE to 2 S albumins has shown

50 ermined by a prototype test (now in clinical diagnostic use) that captures, enriches, and detects dis

51 Singleplex allergy diagnostics using the alpha-Gal analytes CTX and Bos d T

52 We determined the relationship across common diagnostics used to measure malaria prevalence - polymer

53 w-cost portable biosensors for point-of-care diagnostics using traditional optical, mass, or electroa

54 ressed in the literature, 207 for which only diagnostic use was addressed, 565 for which minimal or n